Global Blood Therapeutics reported a GAAP loss of $303.091 million for 2021, up 22.4% from $247.553 million in the previous year. Revenue increased 57.3% to $194.749 million from $123.803 million a year earlier.
Global Blood Therapeutics reported a GAAP loss of $303.091 million for 2021, up 22.4% from $247.553 million in the previous year. Revenue increased 57.3% to $194.749 million from $123.803 million a year earlier. 
ir.gbt.com
English (US) 